Key result
Targeting the SERCA2a pump remains under investigation as a potential therapy for heart failure.
Why the study?
Decreased SERCA2a expression and/or pump activity are key features in HF, prompting interest in developing therapeutic approaches targeting SERCA2a.
Design
Review
Authors
Loading...
SERCA2a targeting in heart failure remains hypothesis-generating; leaves open the need for definitive randomized trials before clinical consideration.
Restoring SERCA2a function via various molecular and pharmacological strategies offers a potential therapeutic avenue for treating heart failure by improving myocardial calcium cycling.
Changwon Kho (2023) conducted a review in Heart failure. SERCA2a-targeted therapy was evaluated. Targeting the sarcoplasmic reticulum Ca-ATPase (SERCA2a) pump is being investigated as a potential therapeutic strategy for heart failure in both preclinical and clinical studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: